Who to call at Quince Therapeutics, Inc., and when
Fundz watches for the moments Quince Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Quince Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Quince Therapeutics, Inc., from your own LinkedIn network
Quince Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
cortexyme.comAI Executive Summary
AI-powered analysis of 8-K filing content
Three Quince Therapeutics directors (June Bray, David Lamond, Christopher Senner) tendered conditional resignations effective two business days after the October 6, 2026 Special Meeting of Stockholders, contingent on shareholder approval of three specific proposals, signaling potential governance restructuring.
Key Takeaways
Three board members have conditionally resigned, with effectiveness tied to shareholder vote outcomes on October 6, 2026
Resignations are contingent on approval of three unspecified proposals, indicating a planned governance transition rather than a crisis departure
1 more takeaway
Related Filings (7)
7 more filings from Quince Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Quince Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.